中国耳鼻咽喉头颈外科
中國耳鼻嚥喉頭頸外科
중국이비인후두경외과
Chinese Archives of Otolaryngology-Head and Neck Surgery
2015年
11期
569-573
,共5页
受体,表皮生长因子%基因%突变%免疫组织化学%鼻腔鼻窦肠型腺癌
受體,錶皮生長因子%基因%突變%免疫組織化學%鼻腔鼻竇腸型腺癌
수체,표피생장인자%기인%돌변%면역조직화학%비강비두장형선암
Receptor,Epidermal Growth Factor%Genes%Mutation%Immunohistochemistry%sinonasal intestinal-type adenocarcinoma
目的：研究鼻腔鼻窦肠型腺癌组织中表皮生长因子受体（epidermal growth factor receptor，EGFR）蛋白的表达及KRAS（kirsten rat sarcoma viral oncogene）和BRAF（B-Raf proto-oncogen）基因的突变及临床意义。方法免疫组化分析EGFR蛋白在肿瘤组织胞内和胞外的表达，并分析磷酸化EGFR（p-EGFR）蛋白的表达情况；以直接测序法和热熔曲线法测定EGFR、KRAS和BRAF基因在肿瘤组织中的突变情况。结果11例鼻腔鼻窦肠型腺癌组织中EGFR蛋白的阳性表达率为72.7%，细胞内、外EGFR蛋白的表达有显著相关性；p-EGFR的阳性表达率为9.1%。EGFR的突变率为9.1%，发生于第19外显子，KRAS和BRAF基因的突变率均为9.1%，分别发生于第2和第15外显子。EGFR蛋白表达及EGFR、KRAS和BRAF基因的突变与患者无进展生存期或总生存期的长短无相关性。结论鼻腔鼻窦肠型腺癌组织中有EGFR蛋白的过表达，显示了肿瘤细胞的异质性；且存在EGFR、KRAS和BRAF基因的突变，突变率相对较低。
目的：研究鼻腔鼻竇腸型腺癌組織中錶皮生長因子受體（epidermal growth factor receptor，EGFR）蛋白的錶達及KRAS（kirsten rat sarcoma viral oncogene）和BRAF（B-Raf proto-oncogen）基因的突變及臨床意義。方法免疫組化分析EGFR蛋白在腫瘤組織胞內和胞外的錶達，併分析燐痠化EGFR（p-EGFR）蛋白的錶達情況；以直接測序法和熱鎔麯線法測定EGFR、KRAS和BRAF基因在腫瘤組織中的突變情況。結果11例鼻腔鼻竇腸型腺癌組織中EGFR蛋白的暘性錶達率為72.7%，細胞內、外EGFR蛋白的錶達有顯著相關性；p-EGFR的暘性錶達率為9.1%。EGFR的突變率為9.1%，髮生于第19外顯子，KRAS和BRAF基因的突變率均為9.1%，分彆髮生于第2和第15外顯子。EGFR蛋白錶達及EGFR、KRAS和BRAF基因的突變與患者無進展生存期或總生存期的長短無相關性。結論鼻腔鼻竇腸型腺癌組織中有EGFR蛋白的過錶達，顯示瞭腫瘤細胞的異質性；且存在EGFR、KRAS和BRAF基因的突變，突變率相對較低。
목적：연구비강비두장형선암조직중표피생장인자수체（epidermal growth factor receptor，EGFR）단백적표체급KRAS（kirsten rat sarcoma viral oncogene）화BRAF（B-Raf proto-oncogen）기인적돌변급림상의의。방법면역조화분석EGFR단백재종류조직포내화포외적표체，병분석린산화EGFR（p-EGFR）단백적표체정황；이직접측서법화열용곡선법측정EGFR、KRAS화BRAF기인재종류조직중적돌변정황。결과11례비강비두장형선암조직중EGFR단백적양성표체솔위72.7%，세포내、외EGFR단백적표체유현저상관성；p-EGFR적양성표체솔위9.1%。EGFR적돌변솔위9.1%，발생우제19외현자，KRAS화BRAF기인적돌변솔균위9.1%，분별발생우제2화제15외현자。EGFR단백표체급EGFR、KRAS화BRAF기인적돌변여환자무진전생존기혹총생존기적장단무상관성。결론비강비두장형선암조직중유EGFR단백적과표체，현시료종류세포적이질성；차존재EGFR、KRAS화BRAF기인적돌변，돌변솔상대교저。
OBJECTIVE To investigate the expression and clinical significance of epidermal growth factor receptor (EGFR), the mutations of gene EGFR, KRAS and BRAF in sinonasal intestinal-type adenocarcinomas. METHODS We investigated the EGFR protein expression by immunohistochemistry method with antibodies targeting the extracellular domain, the intracellular domain, and the phosphorylated isoform in a series of 11sinonasal intestinal-type adenocarcinomas tissues. EGFR, KRAS, and BRAF mutational status were detected by DNA direct sequencing and Melt curve method.RESULTS The findings were analyzed with respect to clinical data, histological typing, and outcome of the patients. EGFR was expressed in 72.7% tumors with a focal distribution with both extracellular domain and intracellular domain, which showed a significantly correlation. p-EGFR was expressed in 9.1% tumors. 9.1% tumors had the mutation of EGFR gene in exon 19, 9.1% tumors had the mutation in exon 2 and exon 15 of gene KRAS and BRAF respectively. There was no association between these molecular features and the survival period of the patients. CONCLUSION The current study revealed various EGFR expression patterns in sinonasal intestinal-type adenocarcinomas, that indicated the tumor heterogeneity. Sinonasal intestinal-type adenocarcinomas share common alterations of the EGFR pathway as the mutation of EGFR, KRAS and BRAF genes, but with a lower frequency.
